Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
If it is like Covid that means they are dropping Billions on BP, not looking for any startup drug.
Partnership. Only way to get the funds to be able to move B forward.
The second of IPIX's trifecta of drugs that appeared to be sure-fire winners was Prurisol, though it was the weakest of the big three to reach commerciality according to those that knew medicine much more than me.
Prurisol was developed by Dr. Menon and if I remember correctly was a "salt" or some such derivative of another drug. Not even sure what that means but it sticks in my mind after all these years.
Prurisol was going to be the drug aimed at treating a slew of dermatological problems, the first and foremost being psoriasis. But during lab work it was said that it showed potential to work against most all auto-immune problems. Here again is another case of a broad spectrum potential drug where all IPIX (or Cellceutix at that time) needed was a few applications to pan out to make it a major winner.
Most long timers will remember that what stood out most regarding Prurisol was a snapshot of about 3-6 mice that showed before and after pictures of treatment with Prurisol. The before pictures showed the mice with mangy, sometimes near no fur, lots of splotches or sores type of skin on the mice and the after pictures showed these beautifully full, pure white, smooth as silk fur coverings.
Prurisol went into its P1 and did fine. Not positive but what I remember about it was that as the dosage rose the results improved as would be expected. It was said the P2 would be run at a slightly higher dosage since no problems were expected and that at the end of the trial it appeared the dosage level was just getting into the peak efficiency range. The other item that was screwy about the trial as I remember (my memory may not be spot on here) was that the trial endpoint was at a cure rate that was astronomically high (like 80% or more). Again, this is a bit jiggy in my memory. I definitely remember saying to myself why the hell did Cellceutix set such a high success rate to meet the trial endpoint.
Well, we went into the trial and it took forever. Again a bit hazy but management somehow got crosswise with the company running the trial in regards to payment or such matter and that put it on hold. Then it was said that Prurisol failed and it was taken off the Cellceutix board as to being a viable drug for further investigation. There were NEVER any results published, there was never any mention of health issues in the trial, there was never any discussion as to its possible use in other auto-immune areas. It just dropped from sight and management (Leo) never gave us sh** as to any kind of explanation.
I know for me that this P2 appeared to be a slam dunk. To have failed so miserably and not have any clue or information as to what went wrong, why it went wrong, why it was pulled from all further investigation, and management treat it as though it was a UFO and not to be discussed under any condition I still to this day find dismaying. Made me think at the time that maybe they sold it on the sly and someone else took it over under a different name or something. I don't think would have been legal but it shows how dismayed, disconcerted, and baffled so many were at the outcome for Prurisol.
Don't have much further to say about Prurisol. It is notable IMO though that all of the IPIX drugs appear to have dropped, or are dropping, out of sight with no real information as to why when they appeared to be such world beaters. Kevetrin is a disgrace and IMO there is no way in hell some BP wouldn't have formed a decent partnership for it, Prurisol is a bit more sketchy but the complete blackout of information since the trial failure appears more in league with a political blackout / lack of transparency, and Brilacidin (which I will discuss this weekend) is still whirling in the spin cycle of "further investigation" when every computer program that has been run lists it as near best in class against broad spectrums of medical issues. Computer data is simply that, factual data, without human input of emotions, greed, criminality, etc and in all cases our drugs were top ranked but when we go to human testing everything goes to shit.
Do BPs have some sort of input with the major hospitals where some worker can slew the results as that would be quite cost effective for BPs, are the CROs (those running the trials) somewhat involved as to final decisions regarding testing data, is the FDA setting ridiculous trial parameters as seemed to be done in the Brilacidin P2 for Covid trial (lower the dosage, lower the dosings, give to far more serious cases that were beyond saving, give to patients taking drugs that lowered B effectiveness, etc). I have no answers for the above, I am just stating that when all the human elements are removed our drugs shine and when human input is involved they turn results on their heads.
For all new investors I would like to give a background as to why so many long term investors are so irate with the medical community, government, allotment of drug development dollars, etc. It is not just because our investment has tanked, it is because we have had a couple of drugs that look like world class life changing drugs that have been totally ignored even when they have shown GREAT potential in earlier studies.
In this post, I will not say anything about Brilacidin as that is worthy of a separate post that I will most likely get to over the weekend. This post is about the company's cancer drug, Kevetrin, the main reason we old timers got into this investment.
Kevetrin was invented by Dr. Krishna Menon, an Indian doctor that led the development of 2 major cancer drug winners for E I Lilly Pharmaceutical Co. in his role as Group Leader, Cancer Invivo Research and Development. He won major awards for this work so it is not as though he was unknowing as to drug development. While working on a bull in the Caribbean as a veterinary surgeon and as the Chief of Agriculture for the Cayman Islands he had a bull come in for hoof and mouth disease. He found that it also was plastered throughout with tumors. He gave it an accepted animal drug for Hoof and Mouth Disease but the bull died. When he cut open the bull to find what specifically caused the death he found that almost all the tumors were gone. He was quite stunned. He took that animal drug and thru his own lab, KARD Research in Boston, he came to develop Kevetrin.
The BIG, BIG hope for Kevetrin was based on the fact that it was the ONLY drug that could turn on the p53 gene. This gene dealt with the body's natural defense and somehow cancer cells were able to turn it off. Kevetrin turned it back on and along with the p21 gene it was said to be able to induce the body's own natural defenses to be able to kill cancer cells, pretty much ALL cancer cells. It was said at the time that the p53 was the most studied subject in the history of medicine. Think about it, a cancer drug that was NON-TOXIC and worked thru natural body processes. The other phenomenal attribute of the drug was that it was said by Dr. Emil Freirich, the acknowledged father of successful treatment of Child Leukemia cases thru his novel idea of combining various treatments together, that if Kevetrin was a kitchen component it would be like sugar or salt in that it could be combined with everything. Think about that, it could be combined with ALL current toxic cancer drugs (which at the time were said to work like agent orange in the body as they killed ALL cells, not just cancer cells) and it made these toxic drugs much less harmful to the body. The thought by IPIX investors was that BP would flock to Kevetrin to make up a cocktail drug combining their drug with K and thus also greatly prolong the patent rights to their drug in this new form.
Studies indicated it could work on retinoblastoma in children where the cancer starts growing right out of the pupil of the eye. Another study put K with a BP cancer drug and the testing showed a reduction in cervical cancer tumors for the first time ever. Yet another study by the U of Bologna in Italy also found extremely positive testing results in some studies of K. To this day, not one damn advancement in any of these major problem areas by the medical community. Why??? Is the Cancer Foundation lacking for funds?? LOL Or is it against the priorities of the largest cancer research organization to actually CURE cancers, not just treat them for life?? If one looks at the enormous amount of jobs that would be lost if cancer was ever cured, one can see that to a VAST number of people that wouldn't be in their best interests. It would be in the best interests of the patients, but it seems they rank much lower on the priority totem pole. This is all strictly my view of the situation.;
IPIX went to a P1 trial (P1 strictly confirms identifying the safety profile of a drug) and the damn trial took a little over 2 years or so to complete (I am not exactly sure but it was a hell of a long time) at the Boston hospital aligned with Harvard (Sloan-Kettering Hospital). Couldn't do much better as to professional validity. What was shocking was that they started the trial at about 2-5 units (I say units as I am unaware of dosage level) but they went up so slowly that it took forever. Long story short, about 2 years later they had done a test for 600 units and all was well. They went up to 800 units and found the additional dosage did nothing positive though it was still perfectly safe. Thus, they ended the trial as no need to go further and they knew 600 units was the max dosage they needed to give and still get 100% efficiency. Also note that each trial took about 2-3 months. So the questions I asked were as follows: what imbecile started the dosage so low that it was basically saline solution, why did they only go up 5, then 10, then 20, etc instead of going much higher and backtracking if necessary as there were only a very few patients in each trial and ALL were terminal so if a few died they weren't really deprived of any meaningful portion of their life and their sacrifice may have helped save many, many others down the line, once they saw the tremendously safe profile of the drug how come NO other BP investigated its use with their current cancer drug, how come no funds came from any portion of government, medical, or charitable organizations, etc, etc. To me there was a complete burying of the drug as IMO they knew it could radically change the treatment and outcome for some types, possibly many types of cancers.
Dr. Freirich stated that he though Kevetrin could possibly work in 50% or more of ALL cancers, IPIX hired the BEST patent attorney for new drugs to make sure they covered all the bases due to the potential of K, there was another very highly touted medical researcher from I believe Columbia U that was on board that was entranced with K, and yet here we sit about a decade later and Kevetrin has not only NOT advanced at all in any theater of cancer research, IPIX suddenly removed it from their website due to lack of funds for further investigation for the foreseeable future and possibly forever if our financial situation doesn't change.
To put it all in a nutshell, the treatment of Kevetrin by medicine is akin to somebody coming up with a transportation device that utilized hydrogen and thus could be acquired at minimal cost with no damage to the environment and the only byproduct would be H2O, it would get very good mileage, and it would be extremely safe as it could be hooked up to an electric motor. Yet it gets buried - would the general public allow that? Well, that is basically what has happened to Kevetrin.
So am I pissed? More than just a little, I believe people should have been sentenced to death for holding this drug back from the public.
My next post will be about Prurisol and following that it will deal with Brilacidin.
According to an article on line today from Fox News Moderna is being sued by 2 firms that say Moderna infringed on their patents in developing their Covid vaccine. The Biden administration is now trying to isolate Moderna from all liability and put all liability on the US Government. How in bed can these BPs and the government be?
Again according to the article, Moderna was given $10B (not million, but BILLION) for Covid development. Covid came out with the vaccine what, about 6-8 months later at the most? How could they have possibly spent anywhere close to $10B for development and since then they have raked in mulitiple Billions for the shots, yet they are not going to be liable for even $1 in repayment if charges are proven true as to the charges?
IPIX can't get one F'ing dollar from the government and yet a BP gets $10B for one development project. This has Dr. Fauci fingerprints all over it IMO due to him being in charge of the INH during this period.
Can stockholders imagine if IPIX had been give just $100MM for B development where we would be today?
One would think when the govt gave Moderna the $10B for development that they would have put in a clause that the govt would get back a certain percentage of the revenues from the vaccine if proved effective and commercialized. They should also have been give a limit on what the govt would spend on development but they would only receive funds as Moderna provided expense receipts. But no, they just wrote a check for an astronomical amount and let them keep it all. Sounds a lot like federal elections where they write leftover funds off for various "campaign" expenses when in reality it many times goes into their pockets or their friends pockets one way or another. Otherwise, why would so many run when they know they don't stand a snowball's chance in hell of even making the debates much less the election.
No doubt it is a stacked deck out there against pharma startups.
That is the question that has all long term investors scratching our heads.
It would seem logical that ONE BP would want to acquire the entire B platform and with its potential give IPIX a decent deal, not asking for a great deal but also not a garbage deal. Seems there would be plenty enough revenues to go around for all concerned.
Observation/question I have is that to date the delivery system for B in all cases seems to be the holdup (IBD pill not refined yet, nasal spray for viral uses not refined yet, OM sachet recently mentioned to need some tweaking which took me completely by surprise, etc). But that should be the role of the BP IMO.
So was/is the holdup Leo not accepting a decent offer or has there been actually NO decent offers which is a head scratcher? To play the Devil's Advocate, what has the DeGrado lab at UCSF actually developed as to a peptide that is currently in use for ANY application as it has been up and running for around 12 years? Are there inherent problems we have overlooked in our belief that B is a near-phenomenal drug and maybe peptides aren't the wonder works they were first touted to be? Just thinking out loud here, not saying this is the case by any means.
I have to believe that even if Leo was valuing B too highly in the past that now he finally realizes IPIX is in survival mode and would be open to more modest offers. Hope that is the case and something develops during the year but not holding my breath.
I think new investors need the full story of how many very distinguished doctors and researchers there has been that extolled the Cellcutix and now Innovation Pharma products over the years and why we feel the handling of this company has been egregiously poor or the medical community/govt/BP/hedge funds have had it in for the company. Hard to believe the medical community has given IPIX 0 dollars to date and though the govt has researched B at their labs at their expense I still wonder if this is to keep it in "eternal investigation mode" or are they actually trying to advance the drug? Why didn't the white paper that was published years ago to the top world virologists not result in any incoming funds for futher non-government research?
This is what I am hoping happens in South America.with U of Sao Paulo efforts and they allow the use of this combo drug for this specific fungal infection for patients on that continent.
Sounds like a no-brainer for Merck to pursue such a combo drug but I still have a fear as to whether the medical community will allow B to be used in any commercial manner as once it shows being extremely effective for one use (whether that be viral, bacterial, fungal, or inflammatory) then they have let a genie out of the bottle which they will never be able to put back in.
I know, at the time it was strictly Kevetrin and Prurisol. I don't get that exact or worry about small stuff in my posts, especially things that happened a decade ago. Dr. Menon was the main reason people invested due to his brilliant career with E I Lilly and successful cancer drugs. Brilacidin came later w/ the PolyMedix technology purchase. When Menon had his auto accident, that's when things started to go gollywampus.
Guess when it took them about 2-3 years to finish the P1 for Kevetrin due to increasing each testing level only minimally that should have told us nobody in the govt wanted to see Kevetrin become a possible savior for a hell of a lot of patients w/ various cancers. Cancer Foundation didn't give a damn, no BP gave a damn, FDA a no go, should have read the writing on the wall then.
Then Brilacidin has an early success in ABSSSI trial against infections and the superbugs that nothing else could killl and it too sits on the shelf for years while many, many die over the years of infections. Same old story.
Now Brilacidin a topic for widespread viruses, bacteria, and fungi and yet it sits basically at the starting line as no money can be found to possibly help out millions worldwide. Guess they should figure out some way that it will help the climate and then it would get unlimited government funds but alas all it can possibly do is save possible untold thousands of lives worldwide.
Because when I invested in IPIX it was 2012. I thought the tremendous science of K and B would overcome the stifling FDA over the years but the recent B Covid trial was the turning point and by then it was too late to get out.
I also didn't realize the uttter futility of Leo as a CEO. He has shown me nothing.
Median cost to develop a cancer drug per the article you referenced is $650MM - some in the medical industry would say that is safety, while to me it is simply obscene.
And yet some have the gall to say the FDA is geared to saving patients?
It is geared to protecting Big Pharma, period!!!!
Are we ever going to see anything progress from all this investigation? Or do the researchers make more money by just doing more research?
The one saving grace I see today is the U of Sao Paulo has an incentive to commercialize Brilacidin as an anti-fungal (they get a royalty on all revenues for same) and maybe that will spur them on to getting B into actual patients in S. America long before the FDA allows the same in the USA. If not for that, the past would indicate that Brilacidin stays in the research spin cycle if left to the FDA/INH/BARDA/military/etc. No faith in US govt agencies PERIOD.
What is with the pure BS delay of report of the research on the 20 viruses with Brilacidin some govt agency did and which we were told cannot be released until Oct, even though the research was finished last spring, because some researcher wanted to use data for their masters thesis or some such joke of a reason.
I find it amazing how often the IPIX uptick is 1.69%. Guess the algorithm gets stuck on that number because it certainly couldn't be happening by random chance - many standard deviations away from that. Investing is a game, on Wall St. though it appears to be a fixed game.
Looked up laser manufacturers on the internet and came up with the following:
https://www.neo-laser.com/
This would appear to be the facility mentioned in the IPIX PR last week
"A tour of an onsite FDA-approved facility where the StingRay System is being manufactured was also conducted."
Note that Neo-Laser's address (can be found under contact us) is the same, HaEshel 7, Caesarea Business Park, Israel as that found for both Shina Systems and BeaMed Tech. Certainly seems that BeaMed T and Shina will not only create the Sting Ray Laser System but manufacture it as well. Sure hope they sell the laser with a royalty/use clause in it so that these machines become royalty generating diamonds for IPIX. Also handy to have all system components housed in the same facility for the rapid advancement of the BeaMed T technology.
Overall, these are all small outfits (Neo-Laser, Shina, BeaMed T) that appear quite capable in their fields and which certainly should be able to scale up as necessary to keep up with product demand when the time comes. Notice in last week's PR from IPIX that they are working with world class suppliers (finally working with the big boys) for components for the system:
"Having already obtained FDA clearance for the laser component of the StingRay System, BeaMed expects soon to make additional requisite submissions to the FDA for clearance of its fiber optics and its software integration package with Siemens and GE imaging systems."
The powers to be in American health have known about Brilacidin and its effectiveness as an antibiotic since the mid teens. Yet not one dollar has been spent to advance it to commercial use though many thousands of patients in the US have died yearly from such infections. At the very least it should have been available as a Compassionate Use option as those results alone would have given them enough data to authorize advancement to FDA approval IMO.
Don't know why they would change their stance now as obviously saving lives seems to be a lesser goal than making sure BP keeps making big bucks off inferior antibiotics, many of which now are ineffective against the worst of the bugs.
What would that kind of market share penetration mean to IPIX stock price? Could we possibly see $1/share sometime in the future if BeaMed highly successful?
BeaMed is located in Caesarea Isreal at HaEshel 7 in the Caesarea Business Park.
https://il.linkedin.com/company/beam-med
https://www.crunchbase.com/organization/shina-systems
Note that they have 2 employees; the two founders of the company, one of whom is a solid state physicist and the other a laser expert.
Other interesting note is that their office location is WITHIN the Shina Systems (corporation founded in 1993 that is among the world leaders in medical imaging and with whom they have relationship in perfecting the needed computer software) building complex in Caesarea.
Can't get much closer than that in working with your primary partner.
It is impressive to date how quickly these Israeli companies have advanced.
The second link I posted above from Crunchbase is confusing to me as it lists Shina Systems as having 11-50 employees, that it is a private company, but most importantly it says that BTMed acquired Shina in Jan '23 under the news section of the linked article. Don't see how BT would have the money needed to buy Shina unless they were able to get a massive loan. If indeed they did, IMO it would show they have plans for this new laser system to revolutionize the field of laser surgery. I am skeptical of this fact as I would have assumed we would have had to have been informed by IPIX of such a move by BeaMed.
The following excerpt is taken from the 10Q recently released by IPX:
In January 2023, the Company was notified by the United States Patent and Trademark Office (USPTO) that its US Patent Application 16/991812 – Host Defense Protein (HDP) Mimetics for Prophylaxis And/Or Treatment of Inflammatory Bowel Diseases of the Gastrointestinal Tract is allowed for issuance as a patent; Notice of Allowance was issued by USPTO on January 25, 2023
Yet recently prior to this IPIX gave up on Kevetrin, as I was informed, due to the high cost of patent renewal costs. The attached information which I downloaded from the internet seems to be quite contradictory to this explanation as patent renewal costs for a non-producing product by a micro to small company (IPIX) is quite low (in the few thousand dollar range for a non-revenue producing product in a micro/small entity (IPIX). Seems ridiculous IMO to give up such a possible billion+ dollar potential cancer product for such a minor fee. I would suggest taking the costs out of the BOD pay as they have done NOTHING to date or maybe Leo could pare his massive UNJUSTIFIED salary to keep KEVETRIN in house.
https://www.upcounsel.com/us-patent-office-maintenance-fees
My distrust in mgt is apparent as I feel IPIX is no longer being run as a public entity and the only information we are ever going to get is from required legal filings or long after the fact.
Will +1 cause any change from +2? Would like to think so but with the technology ready today to go to +0 and the SEC not taking the leap to really end the problem like they should I have my doubts. Guess we will see. Obviously I am happy to see some improvement but still feel too much wiggle room for hedge funds and those dark market folks bankrupting startups to this day.
So who would know the news early? If it is who one would think it most likely be then one can tell the real retail trade shares daily are about zilch.
If news does come tomorrow, then it also shows that the playing field is even more highly skewed than one would first realize.
Our problem due to financial concerns is when????
That sends the importance of this article / patent application a few levels up.
What I don't understand, though, is how he could apply for a patent based on work he did while employed at the FDA (if that is when he came up with his new product) as everything he came across or thought of while working there would have been the property of the USA.
Same as the Air Force Academy female cadet who came up (while at AFA) with a new body armor material that was extremely light yet could stop a .45 bullet at point blank range. She got nothing, everything went to the government. She did get an initial assignment, though, to Cornell to get a PHD in Chemistry.
Since the investigation came from a GOVERNMENTAL LAB at George Mason U (GMU) the author must be the US Government since they would be the owners of the data and results. So IMO we have to assume the government put on the embargo and the only question is why.
As a shareholder my first thought was that the government just has it in for Brilacidin for some reason but that is digging a bit deep IMO.
Could it be that they wanted to protect the data and results until they had a chance to come up with a treatment utilizing Brilacidin and if it used by the military they could permanently hide the data so that foreign countries couldn't benefit from the study?
Bottom line is that between this development and the other major governmental study being by the military I feel any news out of the government this year is slim to none.
Go BeaMedicat Tech!!!!!!!
I do not see any reason why the volume of trading in IPIX should be above minimum levels until we get some positive news. Those still holding won't be selling at this pricing level and there is no news that will bring in new investors.
The laser investment just got together w/ Shina at the start of the year and it is anybody's guess as to how long it will take to get some forward movement worthy of a news release. IMO by this summer would be remarkable. Please note I am not saying anything whatsoever negative about the future of BMT, just that they are working with a new level of imaging that may take a bit to get the software developed. Maybe even by the end of the year would be quite a feat, nobody knows.
I have no faith whatsoever in the govt research moving forward in anything other than glacial speed. Anything faster will be a welcomed surprise.
Bottom line is that there is just not enough happening now to move the price upward and it is anybody's guess as to when that will change. I don't really expect Leo to have any releases to stockholders or to make any other announcements again making IPIX a "quiet zone" for some time to come. Until then, will be in attendance but not making many posts.
You do a good job of beating the drum. Appreciate your efforts.
BeaMed Tech and Shina Systems (BMT's software development partner) are both listed at the same address, HaEshel 7, in the Caesarea Business Park, Israel. No doubt BMT is working out of an office in the Shina office building
Couldn't be better for the BMT - Shina relationship and should allow very fast development IMO
Somebody got the strategic development alliance between BT BeaMed and Shina Systems of 8 Jancompletely out of whack:
https://www.crunchbase.com/acquisition/bt-beamedical-technologies-acquires-shina-systems--a46af711
With the amount of money and the number of jobs that Cancer Research commands, I am sure that they are highly aware of Kevetrin. I also believe that is the reason not one dime has been directed to furthering Kevetrin. Bing answered with the following when I asked about funding raised for Cancer Research each year:
$6.4 billion
How much money is raised each year for cancer research? The FY 2020 funds available to the NCI totaled $6.4 billion (includes $195 million in CURES Act funding), reflecting an increase of 9.2 percent, or $524 million from the previous fiscal year. Funding for Research Areas.
Why would an organization that is truly interested in finding cures and treatments for cancer not throw 1 penny towards Kevetrin when the initial trial results were so positive? Why would not one Big Pharma show interest in acquiring the platform? Protecting their current drugs is my theory.
Follow the money - always, always, always follow the money. Fauci certainly did IMO and that is why he is now a rich man.
So why isn't it being allowed to be tested as a rescue treatment under Compassionate Care for these people dying of fungal infections or going blind due to fungal keratitis?
How many more years of investigation is needed when patients are being left out on the line to die? It already showed it is safe in the ABSSSI clinical trial.
It is criminal IMO not to try and save these patients by using B now for fungal emergencies.
Anybody else believe that if Pfizer owned Brilacidin that the criminal on their board formerly head of the FDA wouldn't have it already being given the OK for treatment? All goes back to the bucks.
Also, where is Leo in this trying to get some deal done? He has been MIA in my opinion.
The data coming out of the U of Sao Paulo regarding the very positive results of B working with the 4 current anti-fungal treatments allowed on the market and the overall effectiveness of it as a broad spectrum anti-fungal makes me quite leery of Basilera finding B not a worthy candidate for their investigations. They may find report different findings than U of SP, but IMO that would be highly unlikely since both organizations are very respected in the fungal infection community of medicine.
Looked up both Shina Systems and BeaMedical Technologies and both are in Israel but neither is in Jerusalem.
Shina is just a few miles from the coast in the northern part of Israel, just south of Caesarea, in an industrial park.
BeaMed I cannot find a good address for but their old name, Squalus Medical, was in the same business park as Shina Systems within a couple of hundred yards. Have to believe they will be working side by side on a daily basis.
Don't see why the Shina (US) facility would get involved with the home offices of both parties so close to each other.
Looking better and better.
Still wouldn't be surprised to see a snap pullback just before the close to finish down for the day as that has seemed to be the pattern the fast few years to all good news.
You are making a mountain out of a mole hill. BeaMed is a private company, IPIX does own a minority stake (about 42% I think) of BeaMed, and BeaMed signed an agreement with Shina to get help in developing the software for the Stingray Laser system as Shina are experts in the world of patient imaging systems.
All things good. We have enough problems without making up more where they don't exist.
Could the PR have been worded a bit better? Sure, since you misinterpreted it, but nothing that will cause any harm.
Looking up Shina Systems shows it to be located in Jerusalem and quite the load carrier in imaging systems world wide. They also have a location in NY. Very involved w/ EU and FDA medical licensing organizations.
Should be a perfect match for BeaMed.
Don't think we could of asked for a more competent partner to push thru the Scorpion Laser Surgery system.
Grass is definitely not going to be growing under this investment.
Many views ranging across the entire spectrum from total pessimism to complete optimism.
I feel both sides have ammo to back their views so I will let the board battle it out.
As for me, I love the science.
History is not on IPIX side, but aren't we currently celebrating an event that nobody saw coming and it changed the world? Same thing could happen to IPIX with all the irons we currently seem to have in the fire.
If Merck has this available now why wouldn't some competitive BP jump all over Brilacidin to keep them on the same playing field as Merck? If they don't have such a platform, they leave Merck a great chance to bury them in the dust in regards to synthetic peptides.
So that means it only has a 60-70% chance of being approved?
Guess IPIX has no Indians, just Chiefs. If she is a Sr. VP one would think there would be regular VPs under her.
I find it disturbing that mgt has visions of grandeur with their titles and pay scale while the common shareholder is just praying for survival.
Also think Leo should send out an end of year update to stockholders as to why 2023 won't become just another "further investigation" year.
At .02 per share the daily average of about 650K shares traded equals $13,000 or so per day.
Put that in perspective as opposed to the share price since if somebody has a very large short position in IPIX they can thus manipulate the price quite easily for next to nothing (as they have very deep pockets and play for the long term). My personal belief is that more than 50% of the daily volume are simply wash trades or naked trades anyway between co-operating MMs or hedge funds.
This is why I look at the current share price as nothing more than a pipe dream trying to suck in as much end of year tax selling as possible .
The flip side is that with all the great forward movement being done currently as to wide spectrum testing of B as an antiviral, anti-fungal, and possibly an early onset COVID use until a partnership has been announced no large influx of investors will be heading into the stock. NO amount of positive TESTING/INVESTIGATING/RESEARCH FINDINGS, as we have seen since last summer, is going to move the stock one iota.
Bottom line is the share price is what it is. Potential looks great but nothing will happen to the share price moving upward until some definite news that shows a large sum of money coming into the IPIX coffers. To remain here, an investor has to accept that premise.
Stock currently is not for the weak of heart.
For any new viewer, Holiday Happy Hour is now in effect until 1/1 so everybody has free Private Messaging until then.
Hard to imagine that anybody would be against IPIX succeeding for all the good that Brilacidin and possibly Kevetrin could do to solve some of the suffering of the world. I can understand some not wanting it to succeed for financial purposes, but to actually want the world to not take advantage of Brilacidin is astounding. What I wrote earlier today regarding 2023 possibilities are just that, possibilities. Nothing more, nothing less, nothing guaranteed. But at least they are things that could happen - so why would anyone want to rain on the IPIX parade?
Go IPIX - not for the investors, but for the world of patients praying for a solution to their pain and suffering.
As for the share price, i am very happy right now with what has happened over the last month and hope that it remains around this price for Jan '23 as investors could then buy or transfer via buying in '23 at low price for regular accounts or holding current shares and buying new shares in Jan '23 for ROTH acct and then selling cash acct shares after good news comes out that raises the share price to equal the $7500 that a senior can put into '23 ROTH so that one has effectively transferred all those shares from a cash acct that is fully taxable to a non-taxable ROTH with a net out of pocket of $0.
Example: Buy 375K shares early Jan @ .02 for a total outlay of cash of .$7500
Then later in Jan or Feb sell whatever amt you can at going price to equal $7500
Say price is .025, you would sell 300K to equal the $7500
Bottom line: You have increased your non-taxable shares by 350K, reduced your taxable shares by 300K, and are out of pocket no money whatsoever.
I am doing this as I have all the shares I want at the current time and need no more. Only in this circumstance would the above example apply.
Last year at this time things looked dismal for IPIX after the failed trial (absolutely worst PR IMO as to promulgating the news) for B-Covid though IMO there appeared to be some expectations for advancement along other lines at that time.
2023 started and some new posters who IMO were blowing smoke came along with wonderful tidings that never took hold and as the year progressed and nothing happened things became bleaker, at least IMO.
All of a sudden summer came and IPIX started a steady march to the end of the year with tremendous news, to wit:
1. Announcement of BMed investment and IMO this is the real sleeper that could propel IPIX forward and take care of our financial distress. Since news of the investment, things have progressed much faster than I believed possible so that now I am expecting some human testing in the first half of 2023. The laser has already been approved by FDA and with the start of a UK trial for a similar (though not as finely tuned) type of laser that BMed can piggyback on those results to get something going in the US quickly. I believe all this possible due to the astounding technical and managerial abilities of its founders. Two ex-Israeli fighter pilots don't let grass grow beneath their feet.
2. Announcement that a paper would be out soon regarding the successful results of the governmental study of B against 23 of the most dangerous viruses known to mankind.
3. Announcement by the government that they were starting a broad spectrum investigation of B as a nasal treatment for soldiers against biological weapons.
4. Announcement that the nasal spray for B could possibly be used as a treatment for early onset COVID as the current vaccines are not able to work against developing variants of COVID and the "failed" trial showed B did work against all variants in an early stage of infection.
5. Announcement by U of Sao Paulo, the highest ranked Univ. in S Amer and #100 in the world, that B was found to work against a broad range of fungal infections and they were doing widespread investigation of same. B was shown to elevate the results of all 4 known commercially approved treatments for fungal infections and these treatments are owned by various BPs to include Merck and Pfizer.
6. U of Sao Paulo also found that B worked as a stand alone product quite effectively against ocular keratitis and could possibly save about 1MM patients per year from losing their eyesight. Leads one to believe it could become a leading ocular treatment for many types of eye conditions.
7. INH/INAID announced that the US govt was starting a broad spectrum investigation of B as an anti-fungal treatment.
8. Year has greatly widened the knowledge of B throughout the medical community so that today most all BPs should have a good idea of the potential of B and many will realize trying to low ball IPIX in attaining it, or even a portion of the platform, is now out of the question and could result in a respectable offer being placed before Leo.
9. Should #8 happen, Leo should be able to negotiate a deal for at least a portion of the B platform such that it relieves the financial pressures and the avenue to fully develop B without further dilution of stock should be possible.
10. Once the financial crisis is avoided and B is fully being developed across many medical arenas, Kevetrin will/may be taken off the shelf (IPIX would have to pay patent fees in arrears) and developed to its full capabilities
11. Last but not least, IMO those that have been trying to keep IPIX stock price low will realize that plan is no longer viable and will leave so that the stock price can rise to the proper level for a startup with a seemingly star drug or two being developed not to mention also having enormous revenue coming in from the BMed investment.
Result: Nothing sure yet, but this Christmas Season is filled with exceedingly high hopes that 2023 will be the year for IPIX to shine.
Anybody else feel there should be a minimum change mandatory for a stock trade. To have it now at 1/100 or even less of a penny is absurd.
IMO it should be at least one penny or two. Current rules allows too much playing around by MMs and hedge funds as no individual investor is giving much credence to a 1/100 cent price of a stock.